The 2016 WHO classification of CNS tumors (2016 CNS WHO) first uses molecular characteristics plus histology to define many tumor entities, such as IDH mutation and EGFR amplification, formulating a concept of how tumor diagnosis should be constructed in the molecular era [3]. This evidence concerns the gene EGFR and neoplasm.